Merkel Cell Carcinoma clinical trials

Explore recruiting merkel cell carcinoma clinical trials.

Recruiting merkel cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Merkel Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controlled, non-comparative Phase II study

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial).

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone, and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or, easily injectable lymph nodes of metastatic/advanced solid tumors.

Belgium, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Multicenter, Open-label, Phase 2 study of Intratumoral Vidutolimod (CMP-001) in Combination with Intravenous Cemiplimab in Subjects with Selected Types of Advanced or Metastatic Cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Merkel Cell Carcinoma trials by city

Merkel Cell Carcinoma clinical trials

Recruiting merkel cell carcinoma studies right now

A Study of VET3-TGI in Patients With Solid Tumors

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Also recruiting in Europe

NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controlled, non-comparative Phase II study

Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial

Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial).

A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers

A Phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone, and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or, easily injectable lymph nodes of metastatic/advanced solid tumors.

A Multicenter, Open-label, Phase 2 study of Intratumoral Vidutolimod (CMP-001) in Combination with Intravenous Cemiplimab in Subjects with Selected Types of Advanced or Metastatic Cancer

Merkel Cell Carcinoma trials by city

Other conditions